Monopar Therapeutics Inc. (MNPR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Monopar Therapeutics Inc. (MNPR) trades at $105.70 with AI Score 70/100 (Grade A). Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics. Market cap: $708M, Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: May 10, 2026MNPR stock analysis for 2026: Analysts have set a consensus price target of $115.00 for Monopar Therapeutics Inc., suggesting 8.8% upside from the current price of $105.70. The AI MoonshotScore is 70/100, indicating a bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
MNPR: 2/3 scored disciplines lean bearish. Dominant signal: Momentum strong.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Monopar Therapeutics Inc. (MNPR) Healthcare & Pipeline Overview
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics, with a primary focus on Validive, a treatment for oral mucositis, and Camsirubicin, a treatment for advanced soft tissue sarcoma. The company also develops MNPR-101 and MNPR-202 for various cancers.
What Is the Investment Thesis for MNPR?
Monopar Therapeutics Inc. presents a high-risk, high-reward investment opportunity typical of clinical-stage biopharmaceutical companies. The primary value driver is the successful completion of Phase 2b/3 clinical trials for Validive, targeting a significant unmet need in preventing oral mucositis. Positive trial results and subsequent FDA approval could lead to substantial revenue generation. Camsirubicin's progress in Phase 1b trials for advanced soft tissue sarcoma represents a secondary value driver. Key risks include clinical trial failures, regulatory hurdles, and the need for additional funding to support ongoing research and development. The company's market capitalization of $708M reflects the speculative nature of its pipeline.
Based on FMP financials and quantitative analysis
MNPR Key Highlights
- Lead product candidate Validive is in Phase 2b/3 clinical trials for the prevention of chemoradiotherapy induced severe oral mucositis.
- Camsirubicin, an analog of doxorubicin, is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma.
- Collaborations with Grupo Español de Investigación en Sarcomas, NorthStar Medical Radioisotopes, LLC, and the Cancer Science Institute of Singapore.
- Market capitalization of $708M reflects the company's clinical-stage status.
- The company has 14 employees, indicating a lean operational structure.
Who Are MNPR's Competitors?
MNPR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RIGL Rigel Pharmaceuticals, Inc. | $37.80 | -3.84% | $699M | 94 |
| ZVRA Zevra Therapeutics, Inc. | $12.52 | +3.13% | $740M | 74 |
| GNFTF Genfit S.A. | $15.95 | +48.37% | $800M | 73 |
| CRMD CorMedix Inc. | $7.94 | -3.05% | $623M | 95 |
| MDXG MiMedx Group, Inc. | $4.13 | -0.96% | $615M | 93 |
| CLYM Climb Bio, Inc. | $12.76 | +1.43% | $870M | 75 |
| TBPH Theravance Biopharma, Inc. | $16.86 | +0.30% | $874M | 97 |
| ABUS Arbutus Biopharma Corporation | $4.47 | +3.23% | $883M | 84 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MNPR's Key Strengths?
- Lead product candidate in Phase 2b/3 clinical trials.
- Diverse pipeline of cancer therapeutics.
- Collaborations with reputable research institutions.
- Experienced management team.
What Are MNPR's Weaknesses?
- Clinical-stage company with no approved products.
- Reliance on successful clinical trial outcomes.
- Need for additional funding to support research and development.
- Small number of employees.
What Could Drive MNPR Stock Higher?
- Completion of Phase 2b/3 clinical trials for Validive.
- Announcement of Phase 1b clinical trial results for Camsirubicin.
- Progression of MNPR-101 and MNPR-202 through preclinical and clinical studies.
- Expansion of strategic collaborations with research institutions and pharmaceutical companies.
What Are the Key Risks for MNPR?
- Negative return on equity (-12.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for Validive, Camsirubicin, or other product candidates.
- Regulatory delays or rejection of marketing applications.
- Competition from established pharmaceutical companies with greater resources.
- Need for additional funding to support research and development.
- Patent challenges or loss of intellectual property protection.
What Are the Growth Opportunities for MNPR?
- Successful Completion of Validive Clinical Trials: The successful completion of Phase 2b/3 clinical trials for Validive represents a significant growth opportunity for Monopar. Oral mucositis is a common and debilitating side effect of cancer treatment, and Validive could address a substantial unmet need. Positive trial results could lead to FDA approval and commercialization, potentially generating significant revenue.
- Advancement of Camsirubicin: The advancement of Camsirubicin through clinical trials for the treatment of advanced soft tissue sarcoma offers another growth avenue. Soft tissue sarcoma is a rare and aggressive cancer, and new treatment options are needed. Positive results from Phase 1b trials could lead to further clinical development and potential commercialization. The market for soft tissue sarcoma treatments is a niche market with potential for high pricing.
- Development of MNPR-101 and MNPR-202: The development of MNPR-101, a urokinase plasminogen activator receptor targeted antibody, and MNPR-202, an analog of camsirubicin, presents additional growth opportunities. These compounds target various types of cancer and could potentially expand Monopar's product pipeline. Preclinical and clinical studies will be necessary to assess their safety and efficacy.
- Strategic Collaborations: Monopar's collaborations with the Grupo Español de Investigación en Sarcomas, NorthStar Medical Radioisotopes, LLC, and the Cancer Science Institute of Singapore provide access to expertise, resources, and potential funding. These collaborations can accelerate the development of Monopar's product pipeline and expand its market reach. Strategic partnerships are crucial for small biotechnology companies to navigate the complex drug development process.
- Expansion into New Therapeutic Areas: While currently focused on cancer therapeutics, Monopar could potentially expand into new therapeutic areas in the future. The company's expertise in drug development and its existing pipeline could be leveraged to address other unmet medical needs. This diversification could reduce the company's reliance on its current product candidates and create new growth opportunities. However, this would require significant investment and strategic planning.
What Opportunities Does MNPR Have?
- Successful commercialization of Validive.
- Expansion of pipeline through internal development and acquisitions.
- Strategic partnerships with pharmaceutical companies.
- Growing demand for cancer therapeutics.
What Threats Does MNPR Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Patent challenges.
What Are MNPR's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Clinical trial data demonstrating efficacy and safety.
- Collaborations with leading research institutions.
- Expertise in cancer drug development.
What Does MNPR Do?
Monopar Therapeutics Inc., incorporated in 2014 and headquartered in Wilmette, Illinois, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for cancer treatment. The company's lead product candidate, Validive, is a clonidine hydrochloride mucobuccal tablet currently in Phase 2b/3 clinical trials. Validive is designed to prevent severe oral mucositis induced by chemoradiotherapy in patients with oropharyngeal cancer. In addition to Validive, Monopar is developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trials for treating advanced soft tissue sarcoma. The company's pipeline also includes MNPR-101, a urokinase plasminogen activator receptor targeted antibody for various cancers; MNPR-101 RIT, a radioimmunotherapeutic for cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin for doxorubicin- and camsirubicin-resistant cancers. Monopar collaborates with the Grupo Español de Investigación en Sarcomas, NorthStar Medical Radioisotopes, LLC, and the Cancer Science Institute of Singapore to advance its research and development efforts.
What Products and Services Does MNPR Offer?
- Develop therapeutics for the treatment of cancer.
- Focus on Validive, a treatment for oral mucositis.
- Develop Camsirubicin, a treatment for advanced soft tissue sarcoma.
- Develop MNPR-101, a urokinase plasminogen activator receptor targeted antibody for various cancers.
- Develop MNPR-101 RIT, a radioimmunotherapeutic for cancer and severe COVID-19.
- Develop MNPR-202, an analog of camsirubicin for doxorubicin- and camsirubicin-resistant cancers.
- Collaborate with research institutions and companies to advance drug development.
How Does MNPR Make Money?
- Develop and commercialize cancer therapeutics.
- Generate revenue through product sales upon regulatory approval.
- Collaborate with other companies and research institutions to share costs and expertise.
- Seek funding through venture capital, grants, and partnerships.
What Industry Does MNPR Operate In?
Monopar Therapeutics Inc. operates within the competitive biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and significant risks of clinical trial failures. The company focuses on developing cancer therapeutics, a market driven by increasing cancer prevalence and the demand for innovative treatments. Monopar's success depends on its ability to navigate the regulatory landscape, secure funding, and differentiate its products from existing therapies. The biotechnology industry is experiencing growth, driven by technological advancements and increased investment in cancer research.
Who Are MNPR's Key Customers?
- Patients with cancer.
- Hospitals and oncology clinics.
- Healthcare providers.
- Research institutions.
FY2026 estForward Outlook
Wall Street analysts project Monopar Therapeutics Inc. revenue of about $400K for fiscal 2026, with EPS near $-2.78. The estimate reflects 8 contributing analysts.
ROE -13%Key Financial Metrics
Return on equity for Monopar Therapeutics Inc. stands at -12.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -10.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 56.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Monopar Therapeutics Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
MNPR Valuation & Market Position
With a $708M market cap, Monopar Therapeutics Inc. sits in the small-cap segment of the market. Relative to its peer group, MNPR's quantitative score of 70/100 is below the peer average of 86/100.
MNPR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Monopar's recent insider buying suggests confidence from those closest to the company, a potentially strong signal.
- The community seems to be focusing on potential catalysts related to their pipeline developments, hinting at upcoming positive news.
- There's a growing perception that MNPR is undervalued, with discussions around its long-term growth potential gaining traction.
- The overall market sentiment seems to be shifting towards smaller biotech firms, potentially benefiting MNPR's visibility and investor interest.
Bear Case
- Recent community discussions highlight concerns about the timeline for Monopar's drug development programs.
- There's a worry that MNPR might need further funding, leading to potential dilution of existing shares.
- Some community members are expressing reservations about the competitive landscape and potential challenges in market adoption.
- The broader market's risk-off sentiment could negatively impact smaller, speculative biotech stocks like MNPR.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MNPR Latest News
-
12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga · Jun 23, 2026
-
Stocks That Hit 52-Week Lows On Friday
benzinga · May 6, 2022
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · May 5, 2022
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · Apr 28, 2022
MNPR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MNPR.
Price Targets
Consensus target: $115.00
MNPR MoonshotScore
What does this score mean?
The MoonshotScore rates MNPR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Chandler D. Robinson
CEO
Chandler D. Robinson serves as the CEO of Monopar Therapeutics Inc. His background includes experience in the biopharmaceutical industry, with a focus on drug development and commercialization. He has held various leadership positions in biotechnology companies, contributing to strategic planning, fundraising, and clinical trial management. His expertise spans oncology and other therapeutic areas, providing a comprehensive understanding of the drug development process. He is responsible for managing a team of 14 employees at Monopar Therapeutics Inc.
Track Record: Under Chandler D. Robinson's leadership, Monopar Therapeutics Inc. has advanced Validive to Phase 2b/3 clinical trials and progressed Camsirubicin to Phase 1b trials. He has also secured collaborations with the Grupo Español de Investigación en Sarcomas, NorthStar Medical Radioisotopes, LLC, and the Cancer Science Institute of Singapore. These achievements reflect his ability to drive the company's strategic objectives and advance its product pipeline.
Monopar Therapeutics Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for MNPR?
MNPR holds an AI Score of 70/100 (Grade: A). This is an educational research signal, not a buy or sell recommendation. Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics. Their lead product candidate, Validive, is in Phase 2b/3 clinical trials …
What does Monopar Therapeutics Inc. do?
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapeutics. Their lead product candidate, Validive, is in Phase 2b/3 clinical trials for the prevention of chemoradiotherapy-induced severe oral mucositis in patients with oropharyngeal cancer.
What do analysts say about MNPR stock?
As of May 10, 2026, analyst coverage of Monopar Therapeutics Inc. (MNPR) is limited due to its clinical-stage nature and small market capitalization. Key valuation metrics are heavily dependent on the successful completion of clinical trials and regulatory approval of its product candidates.
What are the main risks for MNPR?
Monopar Therapeutics Inc. faces several key risks typical of clinical-stage biopharmaceutical companies. These include the risk of clinical trial failures, which could significantly impact the company's valuation and future prospects. Regulatory hurdles and potential delays in obtaining marketing approval for its product candidates also pose a significant risk.
What are the key factors to evaluate for MNPR?
Monopar Therapeutics Inc. (MNPR) holds an AI score of 70/100 (high). Analysts target $115.00 (+9%). Not financial advice.
How frequently does MNPR data refresh on this page?
MNPR's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MNPR's recent stock price performance?
Monopar Therapeutics Inc. (MNPR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Lead product candidate in Phase 2b/3 clinical trials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MNPR overvalued or undervalued right now?
Monopar Therapeutics Inc. (MNPR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $115.00 (+9%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MNPR before investing?
Before investing in Monopar Therapeutics Inc. (MNPR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of May 10, 2026.
- The biotechnology industry is subject to rapid change and inherent uncertainties.